{"id":"W3164370295","doi":"10.1136/annrheumdis-2021-eular.2114","title":"POS0671 CLINICAL RESPONSES TO UPADACITINIB OR ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS BY TYPE OF PRIOR BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG: DATA FROM THE PHASE 3 SELECT-CHOICE STUDY","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"Genentech; CSL Behring; Gilead Sciences; Sanofi; Chugai Pharmaceutical; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Abatacept; Rheumatoid arthritis; Internal medicine; TNF inhibitor; Tocilizumab; Golimumab; Post-hoc analysis; Gastroenterology; Etanercept; Rituximab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002504332,0.00156641,0.002733782,0.0004224829,0.0004176787,0.001168636,0.0006332216,0.001021057,0.004566332],"category_scores_gemma":[0.001521142,0.0004945195,0.003328666,0.0007085557,0.0008862641,0.001243123,0.0003546961,0.002194876,0.001255724],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006704505,"about_ca_system_score_gemma":0.0009218846,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007779592,"about_ca_topic_score_gemma":0.003256717,"domain_scores_codex":[0.999153,0.0004126514,0.00006767237,0.0001109407,0.0001221119,0.0001336776],"domain_scores_gemma":[0.9982293,0.000689992,0.000455708,0.0001329411,0.00009939145,0.0003926435],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9059857,0.004408823,0.02558301,0.0009195001,0.004655917,0.0001255364,0.00008989393,0.00156704,0.007702364,0.0001732255,0.004362274,0.04442664],"study_design_scores_gemma":[0.7657481,0.1071526,0.1132464,0.0001304986,0.004283008,0.0006311773,0.0001299318,0.001439477,0.002091518,0.0004948678,0.004526288,0.0001261496],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866368,0.005740234,0.0002398404,0.0003865706,0.0001211656,0.0003578323,0.004414543,0.0000646108,0.00203836],"genre_scores_gemma":[0.9828515,0.003120372,0.0006266388,0.001035185,0.0002408518,0.0005491184,0.00996786,0.00003660981,0.001571798],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004566332,"threshold_uncertainty_score":0.01527596,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1332728424230976,"score_gpt":0.4270048926955668,"score_spread":0.2937320502724692,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}